Table 1

Baseline clinical characteristics of study subjects

Event-free survival
Overall survival
Characteristicsn (%)Log rankPLog rankP
Histology1222.990.222.970.23
    Invasive ductal96 (78.7)
    Invasive lobular14 (11.5)
    Unspecified12 ( 9.8)
Grading*1182.550.281.490.48
    G15 (4.2)
    G273 (61.9)
    G340 (33.9)
Tumor size1222.200.534.820.19
    T125 (20.5)
    T269 (56.6)
    T316 (13.1)
    T412 (9.8)
Nodal status12228.38<0.00128.32<0.001
    N045 (36.9)
    N167 (54.9)
    N2-310 (8.2)
Metastasis12224.11<0.00117.85<0.001
    M0117 (95.9)
    M15 (4.1)
Stage12224.87<0.00119.11<0.001
    I21 (17.2)
    II69 (56.6)
    III27 (22.1)
    IV5 (4.1)
Menopausal status*760.040.850.290.59
    Premenopausal26 (34.2)
    Postmenopausal50 (65.8)
Estrogen receptor*1150.030.860.830.36
    ER+73 (63.5)
    ER−42 (36.5)
Progesterone receptor*1130.820.370.040.84
    PR+66 (58.4)
    PR−47 (41.6)
HER-2/neu*1130.820.371.580.21
    c-erb-B2+25 (22.1)
    c-erb-B2−88 (77.9)
Recurrence122111.68<0.00157.44<0.001
    Yes67 (54.9)
    No55 (45.1)
  • Abbreviations: ER, estrogen receptor; PR, progesterone receptor.

  • * Number differences reflect missing data.